OBJECTIVES: Triple negative (TN) breast cancer (BC), a subtype of BC characterized by its unique molecular profile and aggressive clinical behavior, lacks satisfactory standard therapies. Little is known about how patients with TNBC were treated in community practice. This study was conducted to identify treatment patterns of first-line chemotherapy (CT) of TNBC using data from community practices. METHODS: Analyses were conducted using the Georgia Cancer Specialist Database (GCSD 2003-2008) and the International Oncology Network’s Treatment and Outcomes Database (ION 2003-2008). In both data, patients with stage IV TNBC were selected and followed for up to one year since initial diagnosis.  The first-line CT was identified if 1) the first drug was initiated within 120 days following the initial BC diagnosis; 2) other combination drugs be started within 30 days of the first drug. RESULTS: The study included 30 and 35 patients from GCSD and ION, respectively. In GCSD sample, 14 patients (47%) were treated with monotherapy, capecitabine and taxanes being dominant (50% and 43%, respectively); 16 patients treated with combination therapy, with carboplatin/gemcitabine+paclitaxel (C/G+P) and cyclophosphomide+doxorubicin (CP+DOX) most frequently used regimens or backbone therapies (31% for each). Other drugs used in combination included docetaxel, bevacizumab, 5-FU and albumin-bound P. Similar patterns were found in ION sample with some deviations: 20 patients (57%) treated with monotherapy, taxanes being dominant (70%); 15 patients treated with combination therapy, C/G+P and CP+DOX/+epirubicin were the most frequently used regimens or backbone therapies (33% for each). Other drugs used in combination included docetaxel, 5-FU, bevacizumab, lapatinib and methotrexate. CONCLUSIONS: It appears that taxanes/capecitabine, and C/G+P or CP+DOX were mostly used monotherapy and combination therapy, respectively, for stage IV TNBC. The patterns are rather diverse than convergent, reflecting lack of standard therapy for TNBC. Data from other community settings are needed to confirm these results.